BioNTech
Tempus, BioNTech Ink Oncology Drug Discovery Research Collaboration
Tempus will provide its real-world multimodal datasets, analytical support, and computational biology expertise to support the development of BioNTech's oncology pipeline.
Qiagen to Develop Companion Diagnostic for BioNTech Head, Neck Cancer Treatment
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
BioNTech Gathering Data Supporting MammaTyper Over Manual, Digital IHC for Breast Cancer Subtyping
Premium
The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome.
BioNTech Inks $310M Personalized Cancer Vaccine Deal With Genentech
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.